Rainbow flag to mark Pride month at Novartis Slovenia
- A rainbow flag was raised in front of Novartis Slovenia headquarters to mark Pride month.
- They joined numerous Novartis countries around the globe celebrating Pride month by this symbolic gesture.
- Novartis is committed to respect human rights of LGBTI+ individuals and maximally ensure inclusive working environment not only in Slovenia but worldwide.
Novartis in Slovenia raised a rainbow flag in front of its headquarters to mark the Pride month and Pride parade, which will take place in Ljubljana and Maribor. By raising the rainbow flag, they joined numerous Novartis countries worldwide to show support and respect for human rights of LGBTI+ individuals.
On this occasion, aspecial event was organized at Novartis Slovenia, which was attended by the Ljubljana Site associates. By this symbolic gesture, they offered their support to diversity and inclusion in workplace and showed respect for all individuals regardless of their sexual orientation. Nejc Jaka Sekula, Global Diversity and Inclusion Head NTO said they aim to enable every associate to be the person they aspire to be and to be proud of it. “In order to do our jobs as efficiently as possible we need to be ourselves. This gives us energy and motivation to create a pleasant working environment. Therefore, we are committed to provide an environment, where associates can express their belief, orientation, and opinion.”
In 2018, Novartis made a public commitment by signing up to the Standards of Conduct for Business, Tackling Discrimination against LGBTI+ individuals. In fact, companies play a vital role in fostering and embedding diversity and promoting culture, respect, and equality. At Novartis and Lek, they are committed to contribute to positive social changes within their area of operation. Respecting human rights, fostering inclusion and responsible business conduct form the basis of their operations.
Novartis is the leading provider of medicines in Slovenia, where Lek, Novartis Pharma Services and Sandoz, operate. Together we are building and maintaining the reputation of a dynamic, ethical, and trusted pharmaceutical company. Lek develops, manufactures, and markets effective, safe, and high quality medicines and active pharmaceutical ingredients. With our knowledge, quality, and experience we have gained an important role in Novartis' organizational structure, especially in the Novartis Technical Operations, Global Drug Development, Novartis Business Services, and the generic division Sandoz. We are the leading Sandoz development center, and one of the key development sites for technologically complex projects. We invest a great deal in the development, education, and training of our employees. Novartis invested in Slovenia more than EUR 2 billion since 2003. More than half of this investment has been devoted to development, and the rest to modernize and expand our production capacities.
Sandoz, a Novartis division, is a global leader in generic pharmaceuticals and biosimilars and a pioneer in the emerging field of prescription digital therapeutics. Our purpose is to pioneer access to healthcare by developing and commercializing novel, affordable approaches that address unmet medical need. Our broad portfolio of high-quality medicines, covering all major therapeutic areas and increasingly focused on value-adding differentiated medicines, accounted for 2018 sales of USD 9.9 billion. Sandoz is headquartered in Holzkirchen, in Germany’s Greater Munich area.
Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach more than 750 million people globally and we are finding innovative ways to expand access to our latest treatments. About 105 thousand people of more than 140 nationalities work at Novartis around the world. Find out more at www.novartis.com
This press release contains statements and conclusions based on projections of Lek’s future business operations. These estimates are derived from the best information currently available. In case these forecasts prove unreliable, the actual results could prove different from those projected.
For additional information contact:
Lek Pharmaceuticals d. d.
Phone: +386 1 580 22 43
Fax: +386 1 580 24 32